Patients with relapsing-remitting multiple sclerosis (MS) treated with daclizumab high-yield process (HYP) had improved cognitive outcomes at 96 weeks compared with beta interferon, a study presented...
Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs) was safe and well tolerated as a regenerative multiple sclerosis (MS) therapy, concluded a first-of...
Delayed-release dimethyl fumarate (DMF) has been associated with significant reductions in confirmed disability progression (CDP) in patients newly diagnosed with relapsing-remitting multiple...
Arbaclofen extended-release tablets (AERT) have proved to have greater tolerability, and similar efficacy and safety, to baclofen in patients with multiple sclerosis (MS), according to randomised...
The effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated to last for up to four years after treatment has started, according to the findings of a...
Regardless of whether the disease is in the progressive phase or not, patients with multiple sclerosis (MS) seem likely to experience relapses for the first time or relapse continuation between the...
No correlation between interferon treatment and antidepressant use has been observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting reported....
Biogen has unveiled new Tecfidera research that, it says, reinforces its efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients and further supports its long-term, well-...
Results from new research suggest that maternal illness and pesticide-related environmental exposure contribute to risk of pediatric-onset multiple sclerosis (MS), whereas cesarean-section delivery...
Results from a "highly promising pilot study" presented at the 68th annual American Academy of Neurology meeting in Canada have shown Lipoic acid is safe, well tolerated, and offers neuroprotection...
